MA31759B1 - Compose amide - Google Patents

Compose amide

Info

Publication number
MA31759B1
MA31759B1 MA32749A MA32749A MA31759B1 MA 31759 B1 MA31759 B1 MA 31759B1 MA 32749 A MA32749 A MA 32749A MA 32749 A MA32749 A MA 32749A MA 31759 B1 MA31759 B1 MA 31759B1
Authority
MA
Morocco
Prior art keywords
amide compound
formula
relates
analgesic
exhibits
Prior art date
Application number
MA32749A
Other languages
Arabic (ar)
English (en)
Inventor
Masakuni Kori
Mitsunori Kouno
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40549244&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31759(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA31759B1 publication Critical patent/MA31759B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne un nouveau composé à cycles fusionnés, qui présente une activité inhibitrice du faah et est utile comme analgésique. L'invention concerne spécifiquement un composé représenté par la formule (i) ci-dessous ou un sel de celui-ci. (dans la formule, les symboles sont tels que définis dans la description).
MA32749A 2007-10-10 2010-04-08 Compose amide MA31759B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007264381 2007-10-10
PCT/JP2008/068369 WO2009048101A1 (fr) 2007-10-10 2008-10-09 Composé amide

Publications (1)

Publication Number Publication Date
MA31759B1 true MA31759B1 (fr) 2010-10-01

Family

ID=40549244

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32749A MA31759B1 (fr) 2007-10-10 2010-04-08 Compose amide

Country Status (21)

Country Link
US (2) US20090163508A1 (fr)
EP (1) EP2199282A4 (fr)
JP (1) JPWO2009048101A1 (fr)
KR (1) KR20100064381A (fr)
CN (1) CN101981010A (fr)
AR (1) AR068764A1 (fr)
AU (1) AU2008311727A1 (fr)
BR (1) BRPI0818366A2 (fr)
CA (1) CA2702171A1 (fr)
CL (1) CL2008002998A1 (fr)
CO (1) CO6270225A2 (fr)
CR (1) CR11358A (fr)
DO (1) DOP2010000104A (fr)
EA (1) EA201070451A1 (fr)
IL (1) IL204970A0 (fr)
MA (1) MA31759B1 (fr)
MX (1) MX2010003918A (fr)
PE (1) PE20090815A1 (fr)
TN (1) TN2010000148A1 (fr)
TW (1) TW200924778A (fr)
WO (1) WO2009048101A1 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR055831A1 (es) 2004-12-30 2007-09-12 Janssen Pharmaceutica Nv Pepirazinilureas y piperidinilureas como moduladores de hidrolasa de amida de acidos grasos
US20080182851A1 (en) * 2006-11-20 2008-07-31 Glenmark Pharmaceuticals S.A. Acetylene derivatives as stearoyl coa desaturase inhibitors
CN101868452B (zh) 2007-10-10 2014-08-06 诺华股份有限公司 螺环吡咯烷类与其对抗hcv和hiv感染的应用
TW200924778A (en) * 2007-10-10 2009-06-16 Takeda Pharmaceutical Amide compound
AU2010223919B2 (en) 2009-03-13 2016-03-31 Les Laboratoires Servier Methods and compositions for cell-proliferation-related disorders
WO2010117014A1 (fr) * 2009-04-08 2010-10-14 武田薬品工業株式会社 Dérivé de triazine
RU2561132C2 (ru) 2009-06-29 2015-08-20 Аджиос Фармасьютикалз, Инк. Производные хинолинсульфонамидов и их применение для модулирования пкм2 активности
EP3561077B1 (fr) 2009-10-21 2022-12-21 Les Laboratoires Servier Procédés pour des troubles liés à la prolifération cellulaire
US20120225097A1 (en) * 2009-11-12 2012-09-06 Hawryluk Natalie A Piperazinecarboxamide derivative useful as a modulator of fatty acid amide hydrolase (faah)
EP2518064A1 (fr) * 2009-12-25 2012-10-31 Mochida Pharmaceutical Co., Ltd. Nouveau derive aryl-uree
WO2011085216A2 (fr) 2010-01-08 2011-07-14 Ironwood Pharmaceuticals, Inc. Utilisation d'inhibiteurs de faah pour traiter la maladie de parkinson et le syndrome des jambes sans repos
MX2012008346A (es) * 2010-01-25 2012-11-12 Chdi Foundation Inc Determinados inhibidores de cinurenina-3-monooxigenasa, composiciones farmceuticas y metodos de uso de los mismos.
WO2011123719A2 (fr) 2010-03-31 2011-10-06 Ironwood Pharmaceuticals, Inc. Utilisation d'inhibiteurs de faah pour le traitement des douleurs abdominales, viscérales et pelviennes
TW201206440A (en) * 2010-04-28 2012-02-16 Astellas Pharma Inc Prophylactic or therapeutic agent for diseases associated with pains in urinary organs
JP2013147430A (ja) * 2010-04-28 2013-08-01 Astellas Pharma Inc 夜間頻尿の予防又は治療剤
UA108233C2 (uk) 2010-05-03 2015-04-10 Модулятори активності гідролази амідів жирних кислот
FR2974729B1 (fr) * 2011-05-02 2013-04-19 Servier Lab Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent
SG194697A1 (en) 2011-05-03 2013-12-30 Agios Pharmaceuticals Inc Pyruvate kinase activators for use in therapy
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CA2841981A1 (fr) * 2011-07-28 2013-01-31 Chdi Foundation, Inc. Certains inhibiteurs de kynurenine-3-mono-oxygenase, compositions pharmaceutiques et leurs procedes d'utilisation
NZ627096A (en) 2012-01-06 2017-02-24 Agios Pharmaceuticals Inc Triazinyl compounds and their methods of use
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
WO2014062511A1 (fr) 2012-10-15 2014-04-24 Agios Pharmaceuticals, Inc. Composés et compositions thérapeutiques
WO2015003360A2 (fr) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Composés thérapeutiquement actifs et leurs méthodes d'utilisation
WO2015003355A2 (fr) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Composés thérapeutiquement actifs et leurs méthodes d'utilisation
CN105593215B (zh) 2013-07-11 2019-01-15 安吉奥斯医药品有限公司 用于治疗癌症的作为idh2突变体抑制剂的2,4-或4,6-二氨基嘧啶化合物
MY185687A (en) 2013-07-11 2021-05-30 Agios Pharmaceuticals Inc N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
KR20240010105A (ko) 2014-03-14 2024-01-23 아지오스 파마슈티컬스 아이엔씨. 치료적으로 활성인 화합물의 약제학적 조성물
FI3307271T3 (fi) 2015-06-11 2023-10-17 Agios Pharmaceuticals Inc Pyruvaattikinaasin aktivaattorien käyttämisen menetelmä
SG11201803088PA (en) 2015-10-15 2018-05-30 Agios Pharmaceuticals Inc Combination therapy for treating malignancies
PT3362066T (pt) 2015-10-15 2021-11-16 Celgene Corp Terapia de combinação para tratar malignidades
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ288002B6 (cs) * 1995-01-11 2001-03-14 Samjin Pharmaceutical Co., Ltd. Piperazinové deriváty a farmaceutický prostředek s protinádorovou aktivitou je obsahující
NZ329847A (en) * 1996-06-29 1999-01-28 Samjin Pharm Co Ltd Piperazine derivatives and process for the preparation thereof
TR200002182T2 (tr) * 1998-01-27 2000-12-21 Aventis Pharmaceuticals Products Inc. İkame edilmiş aksozaherosayklil faktör xa inhibitörleri
US6462054B1 (en) 2000-03-27 2002-10-08 The Scripps Research Institute Inhibitors of fatty acid amide hydrolase
JP2004525071A (ja) * 2000-07-20 2004-08-19 ニューロジェン コーポレイション カプサイシン受容体リガンド
WO2003011220A2 (fr) * 2001-07-31 2003-02-13 The Scripps Research Institute Modele animal pour comportements neurologiques associes a l'amide d'acide gras
US20040063726A1 (en) * 2002-02-08 2004-04-01 Artman Linda D Methods and compounds for treating neurologic or neuropsychiatric disorders and identifying compounds to treat the same
DK1522314T3 (da) * 2002-06-26 2014-05-26 Ono Pharmaceutical Co Midler for sygdomme forårsaget af vaskulær sammentrækning eller udvidelse
EP1535922A4 (fr) 2002-07-11 2006-10-04 Takeda Pharmaceutical Derive de pyrrolopyridine et utilisation de ce dernier
US20080124275A1 (en) * 2002-11-14 2008-05-29 The Scripps Research Institute Crystalline Form of Fatty Acid Amide Hydrolase (Faah)
GB0325956D0 (en) * 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
TW200633990A (en) * 2004-11-18 2006-10-01 Takeda Pharmaceuticals Co Amide compound
WO2007020888A1 (fr) 2005-08-12 2007-02-22 Takeda Pharmaceutical Company Limited Agent protegeant des cellules du cerveau/neuronales et agent therapeutique pour des troubles du sommeil
EP1988900A2 (fr) * 2006-02-23 2008-11-12 Merck & Co., Inc. Derives de pyridine, de pyrimidine et de pyrazine en tant que modulateurs du recepteur cxcr3
TW200924778A (en) * 2007-10-10 2009-06-16 Takeda Pharmaceutical Amide compound

Also Published As

Publication number Publication date
CN101981010A (zh) 2011-02-23
WO2009048101A1 (fr) 2009-04-16
DOP2010000104A (es) 2010-05-15
EP2199282A4 (fr) 2011-04-27
US20090163508A1 (en) 2009-06-25
KR20100064381A (ko) 2010-06-14
EA201070451A1 (ru) 2010-10-29
IL204970A0 (en) 2010-11-30
US20100234389A1 (en) 2010-09-16
TN2010000148A1 (en) 2011-11-11
BRPI0818366A2 (pt) 2015-04-07
TW200924778A (en) 2009-06-16
AU2008311727A2 (en) 2010-05-06
CL2008002998A1 (es) 2009-11-20
CR11358A (es) 2010-07-12
CO6270225A2 (es) 2011-04-20
PE20090815A1 (es) 2009-07-20
EP2199282A1 (fr) 2010-06-23
JPWO2009048101A1 (ja) 2011-02-24
AR068764A1 (es) 2009-12-02
AU2008311727A1 (en) 2009-04-16
CA2702171A1 (fr) 2009-04-16
MX2010003918A (es) 2010-08-04

Similar Documents

Publication Publication Date Title
MA31759B1 (fr) Compose amide
MA34509B1 (fr) Composé hétérocyclique et son utilisation
MA39001A1 (fr) Composés pyridyle substitués par alkyl-amide, utiles comme modulateurs d'il-12, il-23 et/ou de réponses à l'ifn?
MA33209B1 (fr) Inhibiteurs de la replication du virus de l'hepatite c
EA200900018A1 (ru) Керамический фильтр
MA35172B1 (fr) Melanges pestticides contenant des derives d'isoxazoline
EA202091893A1 (ru) Новые кристаллические формы
MA38218A1 (fr) Pyridine-2-amides utiles comme agonistes de cb2
MA32006B1 (fr) Inhibiteurs de polymerase virale
MA31906B1 (fr) Inhibiteurs de la replication du virus de limmunodeficience humaine
PE20040164A1 (es) Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas
UY30941A1 (es) Inhibidores de serina proteasas
EA200601457A1 (ru) Ингибиторы вирусной полимеразы
MA35245B1 (fr) Pyridin-2-amides utiles comme agonistes de cb2
EA201070182A1 (ru) Алкилсульфонилзамещённые тиазолидные соединения
UA110647C2 (uk) Похідне азолу, спосіб його одержання, проміжна сполука і хімічний агент, призначений для застосування в сільському господарстві і садівництві, і агент для захисту промислових матеріалів
EA200802380A1 (ru) Совместные кристаллы пирролидинонов
RU2012148909A (ru) Новый синтез соединений тиазолидиндиона
BR112018004447A2 (pt) derivado de biarila e medicamento contendo o mesmo
MA32985B1 (fr) Nouveaux microbiocides
MA31526B1 (fr) Nouveaux herbicides
MA46039B1 (fr) Dérivé de triazolopyrazinone utile en tant qu'inhibiteur de pde1 humain
EA201170481A1 (ru) Сокристаллы
DOP2011000154A (es) 3-aminociclopentancarboxamidas
MA30664B1 (fr) Derive d'aminoalcool et immunodepresseur le contenant en tant que principe actif.